THERAKOS
Therakos, Inc. is an immunotherapy company focused on providing innovative treatment platforms that harness the power of each individual patient’s immune system to fight disease. We are the global leader in autologous immune cell therapy delivered through extracorporeal photopheresis (ECP).
THERAKOS
Industry:
Health Care Pharmaceutical
Founded:
1984-01-01
Address:
West Chester, Pennsylvania, United States
Country:
United States
Website Url:
http://www.therakos.com
Total Employee:
10001+
Status:
Active
Contact:
4846311000
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Tag Manager Domain Not Resolving Microsoft Exchange Online Amazon Office 365 Mail
Similar Organizations
Crystal Bioscience
Crystal Bioscience is an antibody discovery company.
Oncotelic
Oncotelic is a cancer immunotherapy company
Current Employees Featured
Official Site Inspections
http://www.therakos.com Semrush global rank: 7.74 M Semrush visits lastest month: 437
- Host name: 45.60.240.79
- IP address: 45.60.240.79
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Therakos"
Therakos - Crunchbase Company Profile & Funding
Therakos provides extracorporeal photopheresis immune modulation therapy to enhance immunologic response. It offers Therakos Cellex Photopheresis System, which is used in conjunction with UVADEX (methoxsalen) Sterile Solution to …See details»
About us - Therakos
The THERAKOSâ„¢ CELLEXâ„¢ Photopheresis System has received CE Certification under the European Union Medical Device Regulation (EU MDR). EU MDR laws govern medical devices …See details»
CVC Completes Acquisition of Therakos from Mallinckrodt - Yahoo …
Dec 2, 2024 NEW YORK & RARITAN, N.J. & DUBLIN, December 02, 2024--CVC, a leading global private markets manager, today completed the previously announced acquisition of the …See details»
Therakos Information | Mallinckrodt Pharmaceuticals
Mallinckrodt plc announced on December 2, 2024 that it has completed the previously announced sale of its Therakos business to CVC Capital Partners Fund IX. Click here for more …See details»
CVC Completes Acquisition of Therakos from Mallinckrodt
Oct 21, 2024 Therakos is the leading company in Extracorporeal Photopheresis (ECP) delivery systems for autologous immunomodulatory therapy. With approvals for use in the U.S., …See details»
Mallinckrodt Completes Divestiture of Therakos® Business
Dec 2, 2024 Net Proceeds to Reduce the Company's Net Debt by More Than 60%. DUBLIN , Dec. 2, 2024 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global …See details»
Mallinckrodt Completes Divestiture of Therakos® Business
DUBLIN , Dec. 2, 2024 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it has completed the …See details»
THERAKOS | Canada | Information for Consumers
This website contains information intended only for consumers in Canada looking to learn more about THERAKOS. JUST DIAGNOSED ON TREATMENT. STARTING THERAPY ASK …See details»
Therakos Company Profile 2024: Valuation, Investors, Acquisition ...
Therakos General Information Description. Provider of extracorporeal photopheresis immune modulation therapy intended to help enhance immunologic response. The company …See details»
Therakos
Therakos (UK) Ltd is part of Mallinckrodt Pharmaceuticals. Registered office, 3 Lotus Park, The Causeway, Staines-Upon-Thames, TW18 3AG, UK. Registration No. 08246321. ... transferred …See details»
THERAKOS ECP Immunomodulation | Canada | Healthcare …
THERAKOS Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume …See details»
Photopheresis - THERAKOS
The THERAKOS ® Photopheresis System is an immunomodulatory therapy that uses extracorporeal photopheresis (ECP) to help enhance immunologic response.* THERAKOS …See details»
Therakos Institute
The THERAKOS INSTITUTE TM (also known as TI) brings together innovative learning programs and passionate individuals to help build a community of expert THERAKOS Photopheresis …See details»
Therakos® - Mallinckrodt Pharmaceuticals
Therakos® Cellex® Photopheresis System The THERAKOS® CELLEX® Photopheresis System is indicated for use in the ultraviolet-A (UVA) irradiation, in the presence of the photoactive …See details»
Therakos, Inc. - VentureRadar
Ardena Netherlands n/a Ardena is a fully integrated Contract Development & Manufacturing Organization (CDMO) with a core focus on bringing molecules to the clinics. Epistem United …See details»
Mallinckrodt Completes Divestiture of Therakos® Business - PR …
Dec 2, 2024 Net Proceeds to Reduce the Company's Net Debt by More Than 60%. DUBLIN , Dec. 2, 2024 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global …See details»
CVC Completes Acquisition of Therakos from Mallinckrodt
Dec 2, 2024 The Therakos Photopheresis Systems are now available in more than 350 treatment centres globally. Treatment centres are independent, third-party facilities not owned, …See details»
TherakosInstitute.com
The THERAKOS CELLEX Photopheresis System is indicated for use in the ultraviolet-A (UVA) irradiation, in the presence of the photoactive drug 8-methoxypsoralen (8-MOP ®), of …See details»
THERAKOS Starting Therapy Discussion Guide
ASK ABOUT THERAKOS TM GENERAL QUESTIONS ABOUT THERAKOS Use the questions below to help start a conversation with your healthcare provider and learn about THERAKOS. …See details»
MyTherakos Login | Therakos
The THERAKOSâ„¢ CELLEXâ„¢ Photopheresis System is indicated in patients older than 3 years of age for the management of: Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD) …See details»